Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Outset Medical ( (OM) ) has provided an announcement.
On January 12, 2026, Outset Medical reported preliminary, unaudited results for the fourth quarter and full year 2025, with revenue of approximately $28.9 million in the quarter and about $119.5 million for the year, representing 5% growth over 2024. The company highlighted operational traction, noting more than 1,000 sites of care had insourced dialysis with Outset by the end of 2025, delivering around 1 million treatments annually on its Tablo system, and reported a year-end cash balance of $173 million with net cash used in operations reduced to under $50 million from $116 million in 2024, signaling improved cash efficiency. Outset also announced that experienced medtech executive Karen N. Prange joined its board of directors and Compensation Committee, effective January 9, 2026, replacing outgoing director Andrea Saia, whose departure was not due to any disagreement, a move that bolsters the board’s commercial and acute-care expertise as the company pursues further growth in 2026.
The most recent analyst rating on (OM) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Outset Medical stock, see the OM Stock Forecast page.
Spark’s Take on OM Stock
According to Spark, TipRanks’ AI Analyst, OM is a Neutral.
Outset Medical’s overall stock score is primarily impacted by its financial performance and technical analysis. The company shows strong revenue growth but faces challenges in profitability and cash flow. Technical indicators suggest bearish momentum, and valuation metrics are weak due to ongoing losses. The earnings call provided some positive insights but also highlighted significant challenges.
To see Spark’s full report on OM stock, click here.
More about Outset Medical
Outset Medical, Inc., based in San Jose and listed on Nasdaq as OM, is a medical technology company focused on transforming the dialysis experience across the continuum of care. Its flagship product, the Tablo Hemodialysis System, is an FDA-cleared, integrated dialysis platform designed to reduce the cost and complexity of treatment by combining water purification and on-demand dialysate production, and is deployed in more than 1,000 U.S. healthcare facilities for both hospital and home use.
Average Trading Volume: 549,303
Technical Sentiment Signal: Strong Sell
Current Market Cap: $84.68M
For an in-depth examination of OM stock, go to TipRanks’ Overview page.